Clinical trials: Liver Diseases, Alcoholic
Non-Alcoholic Fatty Liver Disease
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05292911
- Testing
- ALT-801
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Altimmune, Inc.
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease
Aims and objectives: The Investigator aimed to evaluate effect of adjustable intra gastric balloon on non-alcoholic fatty liver disease/non alcoholic steatohepatitis (NAFLD/NASH) with or without diabetes mellitus, who have failed…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04182646
- Testing
- Spartz Balloon
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Asian Institute of Gastroenterology, India
NAFLD
Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
NAFLD, closely linked to overweight and insulin resistance, has reached 25% prevalence worldwide. Advanced liver fibrosis(ALF) must be accurately diagnosed in NAFLD because it defines a subgroup of patients with impaired…
- Trial name
- TRAFIC (NCT04681573)
- Testing
- blood tests
- Where
- 20 sites in France
- Volunteers
- 1,045 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Steatohepatitis (NASH)
Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH
Study type :clinical trial Main purpose :esnsure safety and efficacy of Roflumilast to treat patients with Non-Alcoholic Steatohepatitis Background and aim: Non-alcoholic fatty liver disease is the most prevalent chronic liver…
- Trial name
- NCT06677788
- Testing
- Roflumilast 500 Mcg Oral Tablet, Vitamin E capsule
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT05073588
- Testing
- Indo Mediterranean diet, Calorie restricted diet
- Where
- India
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Fatty Liver Disease
Urinary Metabonomics of Two Major Patterns of NAFLD
NAFLD(non-alcoholic fatty liver disease, NAFLD) is a common liver disease with a high morbidity which seriously influence people's health.
- Trial name
- NCT02077283
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- ShuGuang Hospital
Steatohepatitis
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a…
- Trial name
- NCT05864391
- Testing
- AZD7503
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease
Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver dysfunctions, affects about one-fourth of the global adult population and has a significant mortality rate between 6.3% and 33%.NAFLD can lead to other…
- Trial name
- NAFLD (NCT04049396)
- Testing
- Berberine
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Lida Nejati
Nonalcoholic Fatty Liver
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease
Vitamin D deficiency is very common in patients with fatty liver disease as evidenced by our observations in the Metabolic Liver Clinic and that reported by others.
- Trial name
- NCT03084328
- Testing
- Vitamind D
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The Cleveland Clinic
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
Alcoholic Hepatitis
Fecal Microbiota Therapy in Steroid Ineligible Alcoholic Hepatitis
Alcoholic hepatitis, the most florid form of alcoholic liver disease, has a very high short-term mortality of up to 50% and no specific therapies are available other than steroids.
- Trial name
- NCT05285592
- Testing
- Fecal Transplantation, Standard Medical Treatment
- Where
- India
- Volunteers
- 84 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non Alcoholic Steatohepatitis
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- FLIRT (NCT00492700)
- Testing
- rosiglitazone
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Association pour la Recherche sur les Maladies Hépatiques Virales
Non-Alcoholic Steatohepatitis (NASH)
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects
- Trial name
- NCT04481594
- Testing
- HPN-01
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hepanova Inc.
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
- Trial name
- NCT03976401
- Testing
- EFX
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- Akero Therapeutics, Inc
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
NASH - Nonalcoholic Steatohepatitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Trial name
- NCT04054310
- Testing
- Liver Multi Scan
- Where
- 7 sites in United States
- Volunteers
- 225 people
- Sponsor
- Perspectum
Alcoholic Liver Disease
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
Apart from Fibrotest, non-invasive markers have been validated only for chronic hepatitis C. However as for chronic C hepatitis, non invasive tests (Fibrotest and transient elastometry) are already used in current practice.
- Trial name
- FIBROMAF (NCT00708617)
- Where
- 3 sites in France
- Volunteers
- 227 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease
Assess the renal changes in patients with non-alcoholic fatty liver (NAFLD).
- Trial name
- NCT03487068
- Testing
- The FibroScan device
- Volunteers
- 50 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.